Is CABA or ZBIO more profitable?

Zenas BioPharma's return on equity of -122.45% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Zenas BioPharma N/A -122.45% -58.04%

Does the media refer more to CABA or ZBIO?

In the previous week, Cabaletta Bio had 5 more articles in the media than Zenas BioPharma. MarketBeat recorded 6 mentions for Cabaletta Bio and 1 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.67 beat Cabaletta Bio's score of 0.57 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, CABA or BHVN?

Biohaven is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Biohaven N/A N/A -$738.82M -$4.64 N/A

Is CABA or BHVN more profitable?

Cabaletta Bio's return on equity of -128.27% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Biohaven N/A -1,328.94% -138.27%

Does the media favor CABA or BHVN?

In the previous week, Biohaven had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for Biohaven and 6 mentions for Cabaletta Bio. Biohaven's average media sentiment score of 0.97 beat Cabaletta Bio's score of 0.57 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STOK or CABA?

In the previous week, Stoke Therapeutics had 7 more articles in the media than Cabaletta Bio. MarketBeat recorded 13 mentions for Stoke Therapeutics and 6 mentions for Cabaletta Bio. Stoke Therapeutics' average media sentiment score of 1.07 beat Cabaletta Bio's score of 0.57 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GENB or CABA more profitable?

Generate Biomedicines' return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Cabaletta Bio N/A -128.27% -95.47%

Does the media refer more to GENB or CABA?

In the previous week, Cabaletta Bio had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 6 mentions for Cabaletta Bio and 4 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.70 beat Cabaletta Bio's score of 0.57 indicating that Generate Biomedicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, XNCR or CABA?

Xencor has higher revenue and earnings than Cabaletta Bio. Xencor is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 15.76 -$91.92M -$2.17 N/A Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is XNCR or CABA more profitable?

Cabaletta Bio has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -155.59% -28.66% -20.38% Cabaletta Bio N/A -128.27% -95.47%

Does the media refer more to XNCR or CABA?

In the previous week, Xencor had 7 more articles in the media than Cabaletta Bio. MarketBeat recorded 13 mentions for Xencor and 6 mentions for Cabaletta Bio. Xencor's average media sentiment score of 1.25 beat Cabaletta Bio's score of 0.57 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cabaletta Bio (CABA) Competitors

$3.48 -0.09 (-2.52%)

As of 09/3/2026 04:00 PM Eastern

Compare

CABA vs. ZBIO, BHVN, STOK, GENB, and XNCR

Should you buy Cabaletta Bio stock or one of its competitors? Cabaletta Bio's main competitors and comparable companies include Zenas BioPharma (ZBIO), Biohaven (BHVN), Stoke Therapeutics (STOK), Generate Biomedicines (GENB), and Xencor (XNCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cabaletta Bio compare to Zenas BioPharma?

Cabaletta Bio (NASDAQ:CABA) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Cabaletta Bio has a beta of 3.27, meaning that its share price is 227% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.04, meaning that its share price is 204% less volatile than the broader market.

Cabaletta Bio has higher earnings, but lower revenue than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Zenas BioPharma	$10M	214.57	-$377.74M	-$8.99	N/A

In the previous week, Cabaletta Bio had 5 more articles in the media than Zenas BioPharma. MarketBeat recorded 6 mentions for Cabaletta Bio and 1 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.67 beat Cabaletta Bio's score of 0.57 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Zenas BioPharma's return on equity of -122.45% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Zenas BioPharma	N/A	-122.45%	-58.04%

Cabaletta Bio presently has a consensus price target of $15.33, indicating a potential upside of 340.61%. Zenas BioPharma has a consensus price target of $45.71, indicating a potential upside of 38.86%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Cabaletta Bio is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Cabaletta Bio beats Zenas BioPharma on 8 of the 13 factors compared between the two stocks.

How does Cabaletta Bio compare to Biohaven?

Cabaletta Bio (NASDAQ:CABA) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Biohaven had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for Biohaven and 6 mentions for Cabaletta Bio. Biohaven's average media sentiment score of 0.97 beat Cabaletta Bio's score of 0.57 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio has a beta of 3.27, suggesting that its share price is 227% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Cabaletta Bio presently has a consensus target price of $15.33, indicating a potential upside of 340.61%. Biohaven has a consensus target price of $18.94, indicating a potential upside of 19.10%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Cabaletta Bio is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65

Cabaletta Bio's return on equity of -128.27% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Biohaven	N/A	-1,328.94%	-138.27%

Biohaven is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

88.8% of Biohaven shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cabaletta Bio beats Biohaven on 8 of the 14 factors compared between the two stocks.

How does Cabaletta Bio compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Cabaletta Bio has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Cabaletta Bio	N/A	-128.27%	-95.47%

Stoke Therapeutics has higher revenue and earnings than Cabaletta Bio. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	10.49	-$6.89M	-$3.34	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Stoke Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.27, meaning that its share price is 227% more volatile than the broader market.

Stoke Therapeutics presently has a consensus target price of $44.25, indicating a potential upside of 47.55%. Cabaletta Bio has a consensus target price of $15.33, indicating a potential upside of 340.61%. Given Cabaletta Bio's higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Stoke Therapeutics had 7 more articles in the media than Cabaletta Bio. MarketBeat recorded 13 mentions for Stoke Therapeutics and 6 mentions for Cabaletta Bio. Stoke Therapeutics' average media sentiment score of 1.07 beat Cabaletta Bio's score of 0.57 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Stoke Therapeutics beats Cabaletta Bio on 8 of the 14 factors compared between the two stocks.

How does Cabaletta Bio compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Cabaletta Bio (NASDAQ:CABA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Cabaletta Bio has lower revenue, but higher earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	65.76	-$203.15M	-$1.59	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

In the previous week, Cabaletta Bio had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 6 mentions for Cabaletta Bio and 4 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.70 beat Cabaletta Bio's score of 0.57 indicating that Generate Biomedicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Generate Biomedicines' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Cabaletta Bio	N/A	-128.27%	-95.47%

Generate Biomedicines currently has a consensus price target of $26.40, indicating a potential upside of 61.57%. Cabaletta Bio has a consensus price target of $15.33, indicating a potential upside of 340.61%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Cabaletta Bio beats Generate Biomedicines on 7 of the 12 factors compared between the two stocks.

How does Cabaletta Bio compare to Xencor?

Xencor (NASDAQ:XNCR) and Cabaletta Bio (NASDAQ:CABA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Cabaletta Bio has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
Cabaletta Bio	N/A	-128.27%	-95.47%

Xencor has higher revenue and earnings than Cabaletta Bio. Xencor is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	15.76	-$91.92M	-$2.17	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

In the previous week, Xencor had 7 more articles in the media than Cabaletta Bio. MarketBeat recorded 13 mentions for Xencor and 6 mentions for Cabaletta Bio. Xencor's average media sentiment score of 1.25 beat Cabaletta Bio's score of 0.57 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor presently has a consensus target price of $30.71, indicating a potential upside of 15.38%. Cabaletta Bio has a consensus target price of $15.33, indicating a potential upside of 340.61%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Xencor has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.27, suggesting that its share price is 227% more volatile than the broader market.

Summary

Xencor and Cabaletta Bio tied by winning 6 of the 12 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CABA vs. The Competition

Export

Metric	Cabaletta Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$605.28M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-2.22	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	2.81	16.29	12.89	6.14
Net Income	-$167.86M	-$22.72M	$3.47B	$349.01M
7 Day Performance	11.54%	0.34%	0.60%	-0.27%
1 Month Performance	25.86%	8.52%	5.73%	0.68%
1 Year Performance	125.97%	52.66%	25.35%	14.84%

Cabaletta Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CABA Cabaletta Bio	2.3431 of 5 stars	$3.48 -2.5%	$15.33 +340.6%	+121.7%	$605.28M	N/A	N/A	50	Analyst Forecast
ZBIO Zenas BioPharma	2.7107 of 5 stars	$31.65 -2.0%	$45.71 +44.4%	+92.1%	$2.10B	$10M	N/A	N/A	Positive News
BHVN Biohaven	2.5383 of 5 stars	$13.67 -1.3%	$21.75 +59.1%	-1.9%	$2.09B	N/A	N/A	239
STOK Stoke Therapeutics	3.2708 of 5 stars	$32.32 +0.1%	$44.25 +36.9%	+51.7%	$2.08B	$184.42M	N/A	100	Positive News Insider Trade
GENB Generate Biomedicines	2.4136 of 5 stars	$17.72 +9.9%	$25.40 +43.3%	N/A	$2.07B	$26.48M	N/A	312	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CABA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cabaletta Bio (CABA) Competitors

CABA vs. ZBIO, BHVN, STOK, GENB, and XNCR

How does Cabaletta Bio compare to Zenas BioPharma?

Summary

How does Cabaletta Bio compare to Biohaven?

Summary

How does Cabaletta Bio compare to Stoke Therapeutics?

Summary

How does Cabaletta Bio compare to Generate Biomedicines?

Summary

How does Cabaletta Bio compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cabaletta Bio (CABA) Competitors

CABA vs. ZBIO, BHVN, STOK, GENB, and XNCR

How does Cabaletta Bio compare to Zenas BioPharma?

Which has more risk and volatility, CABA or ZBIO?

Which has preferable valuation and earnings, CABA or ZBIO?

Does the media refer more to CABA or ZBIO?

Is CABA or ZBIO more profitable?

Do analysts rate CABA or ZBIO?

Summary

How does Cabaletta Bio compare to Biohaven?

Does the media favor CABA or BHVN?

Which has more risk & volatility, CABA or BHVN?

Do analysts recommend CABA or BHVN?

Is CABA or BHVN more profitable?

Which has preferable earnings and valuation, CABA or BHVN?

Do insiders & institutionals believe in CABA or BHVN?

Summary

How does Cabaletta Bio compare to Stoke Therapeutics?

Is STOK or CABA more profitable?

Which has higher earnings and valuation, STOK or CABA?

Which has more risk and volatility, STOK or CABA?

Do analysts prefer STOK or CABA?

Does the media prefer STOK or CABA?

Summary

How does Cabaletta Bio compare to Generate Biomedicines?

Which has preferable valuation and earnings, GENB or CABA?

Does the media refer more to GENB or CABA?

Is GENB or CABA more profitable?

Do analysts prefer GENB or CABA?

Summary

How does Cabaletta Bio compare to Xencor?

Is XNCR or CABA more profitable?

Which has better earnings & valuation, XNCR or CABA?

Does the media refer more to XNCR or CABA?

Do analysts prefer XNCR or CABA?

Which has more volatility and risk, XNCR or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools